{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:54:50Z","timestamp":1791647690364,"version":"4.3.4"},"reference-count":294,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3500202"],"award-info":[{"award-number":["2022YFC3500202"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104179"],"award-info":[{"award-number":["82104179"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.intimp.2024.113709","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T13:21:30Z","timestamp":1733491290000},"page":"113709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Ankylosing spondylitis: From pathogenesis to therapy"],"prefix":"10.1016","volume":"145","author":[{"given":"Yuxiao","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenli","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1425-0089","authenticated-orcid":false,"given":"Yang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0005","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41584-020-00552-4","article-title":"Axial spondyloarthritis: concept, construct, classification and implications for therapy","volume":"17","author":"Robinson","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0010","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1136\/annrheumdis-2021-221035","article-title":"Axial spondyloarthritis","volume":"80","author":"Navarro-Comp\u00e1n","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41584-022-00833-0","article-title":"Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis","volume":"18","author":"Stovall","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113709_b0020","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/annrheumdis-2013-eular.1558","article-title":"Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-regression analysis","volume":"72","author":"Stolwijk","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"10089","key":"10.1016\/j.intimp.2024.113709_b0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b0030","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthrit Care Res."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b0035","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/rheumatology\/kez090","article-title":"Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data","volume":"58","author":"Redeker","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0040","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/rheumatology\/24.3.242","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and Modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis","volume":"24","author":"Goie The","year":"1985","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113709_b0045","first-page":"1094","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"74","author":"Ramiro","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 11","key":"10.1016\/j.intimp.2024.113709_b0050","first-page":"S47","volume":"63","author":"Zochling","year":"2011","journal-title":"Arthritis Care Res. (Hoboken)."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b0055","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3899\/jrheum.151244","article-title":"The minimum clinically important improvement and patient-acceptable symptom state in the BASDAI and BASFI for patients with ankylosing spondylitis","volume":"43","author":"Kviatkovsky","year":"2016","journal-title":"J. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0060","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/ar4144","article-title":"Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?","volume":"15","author":"Ramiro","year":"2013","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0065","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrrheum.2017.56","article-title":"Pathogenesis of ankylosing spondylitis - recent advances and future directions","volume":"13","author":"Ranganathan","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","article-title":"Treatment of axial spondyloarthritis: an update","volume":"18","author":"Danve","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.rdc.2017.04.006","article-title":"Genetics and the causes of ankylosing spondylitis","volume":"43","author":"Hanson","year":"2017","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"6142","key":"10.1016\/j.intimp.2024.113709_b0080","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/bmj.2.6142.961-d","article-title":"HLA B27 and risk of ankylosing spondylitis","volume":"2","author":"Dixon","year":"1978","journal-title":"Br. Med. J."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0085","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/ard.37.6.504","article-title":"HLA B27 and the genetics of ankylosing spondylitis","volume":"37","author":"Woodrow","year":"1978","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113709_b0090","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","article-title":"Hla-B27","volume":"33","author":"Bowness","year":"2015","journal-title":"Annu. Rev. Immunol."},{"issue":"7809","key":"10.1016\/j.intimp.2024.113709_b0095","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0140-6736(73)91360-3","article-title":"Ankylosing spondylitis and HL-A 27","volume":"1","author":"Brewerton","year":"1973","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"National Arthritis Data W, Estimates of the prevalence of arthritis and other rheumatic conditions in the United States","volume":"58","author":"Helmick","year":"2008","journal-title":"Part i, Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0105","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1136\/ard.44.6.359","article-title":"Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway","volume":"44","author":"Gran","year":"1985","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/14397595.2013.852856","article-title":"Association of HLA-B27 genetic polymorphisms with ankylosing spondylitis susceptibility worldwide: a meta-analysis","volume":"24","author":"Yang","year":"2014","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0115","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/annrheumdis-2018-213779","article-title":"HLA class I and II alleles in susceptibility to ankylosing spondylitis","volume":"78","author":"Reveille","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0120","first-page":"5263","article-title":"Screening of underlying genetic biomarkers for ankylosing spondylitis","volume":"19","author":"Fan","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1093\/mr\/roac008","article-title":"A multicentre study of clinical features and HLA typing in Japanese patients with ankylosing spondylitis","volume":"33","author":"Tada","year":"2023","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0130","article-title":"Targeting local lymphatics to ameliorate heterotopic ossification via FGFR3-BMPR1a pathway","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b0135","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1002\/art.1780401015","article-title":"Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment","volume":"40","author":"Brown","year":"1997","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/art.1780270301","article-title":"The risk of developing ankylosing spondylitis in HLA-B27 positive individuals. A comparison of relatives of spondylitis patients with the general population","volume":"27","author":"van der Linden","year":"1984","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0145","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2021-222083","article-title":"Factors predicting axial spondyloarthritis among first-degree relatives of probands with ankylosing spondylitis: a family study spanning 35 years","volume":"81","author":"van der Linden","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0150","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1136\/ard.55.4.268","article-title":"HLA class I associations of ankylosing spondylitis in the white population in the United Kingdom","volume":"55","author":"Brown","year":"1996","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0155","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.rdc.2017.04.006","article-title":"Genetics and the causes of ankylosing spondylitis","volume":"43","author":"Hanson","year":"2017","journal-title":"Rheum. Dis. Clin. N. Am."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0160","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/14397595.2016.1206174","article-title":"New insights toward the pathogenesis of ankylosing spondylitis; genetic variations and epigenetic modifications","volume":"27","author":"Mahmoudi","year":"2017","journal-title":"Mod. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0165","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0889-857X(03)00029-2","article-title":"Familial and genetic aspects of spondyloarthropathy","volume":"29","author":"Breban","year":"2003","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b0170","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s10067-021-05679-7","article-title":"Ankylosing spondylitis risk factors: a systematic literature review","volume":"40","author":"Hwang","year":"2021","journal-title":"Clin. Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/ng.513","article-title":"Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci","volume":"42","author":"Australo-Anglo-American Spondyloarthritis","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.intimp.2024.113709_b0180","doi-asserted-by":"crossref","unstructured":"International Genetics of Ankylosing Spondylitis C, A. Cortes, J. Hadler, J.P. Pointon, P.C. Robinson, T. Karaderi, P. Leo, K. Cremin, K. Pryce J. Harris S. Lee K.B. Joo S.C. Shim M. Weisman M. Ward X. Zhou H.J. Garchon G. Chiocchia J. Nossent B.A. Lie O. Forre J. Tuomilehto K. Laiho L. Jiang Y. Liu X. Wu L.A. Bradbury D. Elewaut R. Burgos-Vargas S. Stebbings L. Appleton C. Farrah J. Lau T.J. Kenna N. Haroon M.A. Ferreira J. Yang J. Mulero J.L. Fernandez-Sueiro M.A. Gonzalez-Gay C. Lopez-Larrea P. Deloukas P. Donnelly, C. Australo-Anglo-American Spondyloarthritis, S. Groupe Francaise d'Etude Genetique des, S. Nord-Trondelag Health, Spondyloarthritis Research Consortium of C, Wellcome Trust Case Control C, P. Bowness K. Gafney H. Gaston D.D. Gladman P. Rahman W.P. Maksymowych H. Xu J.B. Crusius I.E. van der Horst-Bruinsma C.T. Chou R. Valle-Onate C. Romero-Sanchez I.M. Hansen F.M. Pimentel-Santos R.D. Inman V. Videm J. Martin M. Breban J.D. Reveille D.M. Evans T.H. Kim B.P. Wordsworth M.A. Brown, Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci, Nat. Genet. 45(7) (2013) 730-738. doi: 10.1038\/ng.2667.","DOI":"10.1038\/ng.2667"},{"key":"10.1016\/j.intimp.2024.113709_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.603726","article-title":"Perspectives on the genetic associations of ankylosing spondylitis","volume":"12","author":"Wordsworth","year":"2021","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0190","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41584-021-00625-y","article-title":"Ankylosing spondylitis: an autoimmune or autoinflammatory disease?","volume":"17","author":"Mauro","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0195","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/ng.1005","article-title":"A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis","volume":"44","author":"Lin","year":"2011","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b0200","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/gene.2014.46","article-title":"Genetic associations and functional characterization of M1 aminopeptidases and immune-mediated diseases","volume":"15","author":"Agrawal","year":"2014","journal-title":"Genes Immun."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0889-857X(21)00705-5","article-title":"HLA-B27 and disease: a consequence of inadvertent antigen presentation?","volume":"18","author":"Benjamin","year":"1992","journal-title":"Rheum. Dis. Clin. North Am."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b0210","doi-asserted-by":"crossref","DOI":"10.3390\/biom10101461","article-title":"Understanding the pathogenesis of spondyloarthritis","volume":"10","author":"Sharip","year":"2020","journal-title":"Biomolecules"},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b0215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11926-019-0856-3","article-title":"The pathogenesis of ankylosing spondylitis: an update","volume":"21","author":"Pedersen","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2024.113709_b0220","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.iy.13.040195.003103","article-title":"The three-dimensional structure of peptide-MHC complexes","volume":"13","author":"Madden","year":"1995","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0225","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","article-title":"Molecular mimicry as a mechanism of autoimmune disease","volume":"42","author":"Cusick","year":"2012","journal-title":"Clin. Rev. Allergy Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0230","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/art.40028","article-title":"Discovery of T cell receptor beta motifs specific to HLA-B27-positive ankylosing spondylitis by deep repertoire sequence analysis","volume":"69","author":"Faham","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0235","first-page":"376","article-title":"Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response","volume":"119","author":"Dazert","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b0240","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/0092-8674(90)90512-D","article-title":"Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders","volume":"63","author":"Hammer","year":"1990","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0245","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.4049\/jimmunol.170.2.1099","article-title":"CD8 alpha beta T cells are not essential to the pathogenesis of arthritis or colitis in HLA-B27 transgenic rats","volume":"170","author":"May","year":"2003","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0250","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s10067-015-3117-5","article-title":"The role of the unfolded protein response in axial spondyloarthritis","volume":"35","author":"Smith","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0255","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/art.39948","article-title":"Polymorphisms in the F Pocket of HLA-B27 subtypes strongly affect assembly, chaperone interactions, and heavy-chain misfolding","volume":"69","author":"Guiliano","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0260","doi-asserted-by":"crossref","first-page":"6665","DOI":"10.4049\/jimmunol.163.12.6665","article-title":"Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies","volume":"163","author":"Mear","year":"1999","journal-title":"J. Immunol."},{"issue":"26","key":"10.1016\/j.intimp.2024.113709_b0265","doi-asserted-by":"crossref","first-page":"23459","DOI":"10.1074\/jbc.M110336200","article-title":"HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum","volume":"277","author":"Dangoria","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0270","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.0105-2896.2009.00865.x","article-title":"From HLA-B27 to spondyloarthritis: a journey through the ER","volume":"233","author":"Colbert","year":"2010","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b0275","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/ncb0805-766","article-title":"ERAD: the long road to destruction","volume":"7","author":"Meusser","year":"2005","journal-title":"Nat. Cell Biol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00281-020-00833-w","article-title":"Aberrant antigen processing and presentation: key pathogenic factors leading to immune activation in Ankylosing spondylitis","volume":"43","author":"Nakamura","year":"2021","journal-title":"Semin. Immunopathol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0285","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/art.22295","article-title":"HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease","volume":"56","author":"Turner","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b0290","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1002\/art.41281","article-title":"HLA-B27 subtypes predisposing to ankylosing spondylitis accumulate in an endoplasmic reticulum-derived compartment apart from the peptide-loading complex","volume":"72","author":"Jah","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b0295","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/eji.200635997","article-title":"Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide","volume":"37","author":"Kollnberger","year":"2007","journal-title":"Eur. J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0300","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/rheumatology\/keg097","article-title":"Breaking the rules: the unconventional recognition of HLA-B27 by CD4+ T lymphocytes as an insight into the pathogenesis of the spondyloarthropathies","volume":"42","author":"Boyle","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2024.113709_b0305","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0310","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.4049\/jimmunol.1102711","article-title":"HLA-B27 homodimers and free H chains are stronger ligands for leukocyte Ig-like receptor B2 than classical HLA class I","volume":"188","author":"Giles","year":"2012","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b0315","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1002\/art.21395","article-title":"Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis","volume":"52","author":"Chan","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0320","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.4049\/jimmunol.1002653","article-title":"Th17 cells expressing KIR3DL2+ and responsive to HLA-B27 homodimers are increased in ankylosing spondylitis","volume":"186","author":"Bowness","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2024.113709_b0325","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.3389\/fimmu.2018.02463","article-title":"How ERAP1 and ERAP2 shape the peptidomes of disease-associated MHC-I proteins","volume":"9","author":"Lopez de Castro","year":"2018","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0330","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/ni860","article-title":"The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues","volume":"3","author":"York","year":"2002","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0335","doi-asserted-by":"crossref","first-page":"901","DOI":"10.4049\/jimmunol.1302855","article-title":"ERAP1-ERAP2 dimerization increases peptide-trimming efficiency","volume":"193","author":"Evnouchidou","year":"2014","journal-title":"J. Immunol."},{"issue":"47","key":"10.1016\/j.intimp.2024.113709_b0340","doi-asserted-by":"crossref","first-page":"17107","DOI":"10.1073\/pnas.0500721102","article-title":"The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a \u201cmolecular ruler\u201d mechanism","volume":"102","author":"Chang","year":"2005","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0345","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/annrheumdis-2011-200347","article-title":"Endoplasmic reticulum aminopeptidase 1 (ERAP1) exhibits functionally significant interaction with HLA-B27 and relates to subtype specificity in ankylosing spondylitis","volume":"71","author":"Haroon","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b0350","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1074\/mcp.M112.019588","article-title":"Functional interaction of the ankylosing spondylitis-associated endoplasmic reticulum aminopeptidase 1 polymorphism and HLA-B27 in vivo","volume":"11","author":"Garcia-Medel","year":"2012","journal-title":"Mol. Cell. Proteomics"},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b0355","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/08916934.2013.819855","article-title":"Endoplasmic reticulum aminopeptidase-1 alleles associated with increased risk of ankylosing spondylitis reduce HLA-B27 mediated presentation of multiple antigens","volume":"46","author":"Seregin","year":"2013","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0360","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ni1286","article-title":"The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules","volume":"7","author":"Hammer","year":"2006","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b0365","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrrheum.2010.85","article-title":"Endoplasmic reticulum aminopeptidases: Biology and pathogenic potential","volume":"6","author":"Haroon","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0370","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.4049\/jimmunol.171.12.6814","article-title":"Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding","volume":"171","author":"Cui","year":"2003","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0375","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI0213847","article-title":"Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding","volume":"110","author":"Cui","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b0380","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/ng.873","article-title":"Australo-Anglo-American Spondyloarthritis C, Wellcome Trust Case Control C, Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility","volume":"43","author":"Evans","year":"2011","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0385","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1034\/j.1399-0039.2002.600301.x","article-title":"Lopez de Castro JA, HLA-B27 and the pathogenesis of spondyloarthritis","volume":"60","author":"Ramos","year":"2002","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.intimp.2024.113709_b0390","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3899\/jrheum.180135","article-title":"The role of the microbiome in gut and joint inflammation in psoriatic arthritis and spondyloarthritis","volume":"94","author":"Gilis","year":"2018","journal-title":"J. Rheumatol. Suppl."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0395","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1084\/jem.180.6.2359","article-title":"The germ-free state prevents development of gut and joint inflammatory disease in Hla-B27 transgenic rats","volume":"180","author":"Taurog","year":"1994","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0400","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2019-215763","article-title":"Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition","volume":"79","author":"Yin","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0405","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.38967","article-title":"Brief report: intestinal dysbiosis in ankylosing spondylitis","volume":"67","author":"Costello","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0410","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.113709_b0415","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.637829","article-title":"Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview","volume":"12","author":"Schinocca","year":"2021","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0420","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/annrheumdis-2016-210000","article-title":"Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis","volume":"76","author":"Ciccia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113709_b0425","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cca.2019.07.038","article-title":"Fecal microbiota in patients with ankylosing spondylitis: correlation with dietary factors and disease activity","volume":"497","author":"Zhang","year":"2019","journal-title":"Clin. Chim. Acta"},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0430","doi-asserted-by":"crossref","first-page":"e0306792","DOI":"10.1371\/journal.pone.0306792","article-title":"Causal relationship between gut microbiota and ankylosing spondylitis and potential mediating role of inflammatory cytokines: a mendelian randomization study","volume":"19","author":"Du","year":"2024","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0435","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/ard.37.2.146","article-title":"Sequential studies in ankylosing spondylitis. Association of klebsiella pneumoniae with active disease","volume":"37","author":"Ebringer","year":"1978","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0440","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/1756-185X.14283","article-title":"Association between Klebsiella pneumoniae and ankylosing spondylitis: a systematic review and meta-analysis","volume":"25","author":"Long","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0445","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1136\/ard.45.3.261","article-title":"Ankylosing spondylitis, HLA-B27, and klebsiella","volume":"45","author":"Geczy","year":"1986","journal-title":"Ann. Rheum. Dis."},{"issue":"4 Suppl 2","key":"10.1016\/j.intimp.2024.113709_b0450","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/rheumatology\/XXII.suppl_2.53","article-title":"The cross-tolerance hypothesis, HLA-B27 and ankylosing spondylitis","volume":"22","author":"Ebringer","year":"1983","journal-title":"Br. J. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0455","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1084\/jem.166.1.173","article-title":"Autoantibodies to HLA B27 in the sera of HLA B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with klebsiella pneumoniae as potential mechanism of autoimmune disease","volume":"166","author":"Schwimmbeck","year":"1987","journal-title":"J. Exp. Med."},{"issue":"7941","key":"10.1016\/j.intimp.2024.113709_b0460","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41586-022-05501-7","article-title":"Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides","volume":"612","author":"Yang","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0465","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/annrheumdis-2018-213532","article-title":"Salmonella exploits HLA-B27 and host unfolded protein responses to promote intracellular replication","volume":"78","author":"Antoniou","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"8872","key":"10.1016\/j.intimp.2024.113709_b0470","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/0140-6736(93)91760-J","article-title":"Hla-B27-restricted Cd8 T-Cells derived from synovial-fluids of patients with reactive arthritis and ankylosing-spondylitis","volume":"342","author":"Hermann","year":"1993","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b0475","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1002\/art.11270","article-title":"Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies","volume":"48","author":"Shi","year":"2003","journal-title":"Arthritis Rheum-Us."},{"key":"10.1016\/j.intimp.2024.113709_b0480","first-page":"1104","article-title":"Cysteine carboxyethylation generates neoantigens to induce HLA-restricted autoimmunity","volume":"379(6637)","author":"Zhai","year":"2023","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b0485","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/art.41252","article-title":"Altered repertoire diversity and disease-associated clonal expansions revealed by T cell receptor immunosequencing in ankylosing spondylitis patients","volume":"72","author":"Hanson","year":"2020","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2024.113709_b0490","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41586-022-05501-7","article-title":"Autoimmunity-associated T cell receptors recognize HLA-B*27-bound peptides","volume":"612(7941)","author":"Yang","year":"2022","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b0495","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.38763","article-title":"Role of protein phosphatase magnesium-dependent 1A and anti-protein phosphatase magnesium-dependent 1A autoantibodies in ankylosing spondylitis","volume":"66","author":"Kim","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0500","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5114\/ceji.2019.92805","article-title":"Biological and genetic evaluation of IL-23\/IL-17 pathway in ankylosing spondylitis patients","volume":"44","author":"Deveci","year":"2019","journal-title":"Cent Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b0505","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.4049\/jimmunol.0711823","article-title":"RANK-RANKL signaling pathway is critically involved in the function of CD4 CD25 regulatory T cells in chronic colitis","volume":"182","author":"Totsuka","year":"2009","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0510","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat. Med."},{"issue":"17","key":"10.1016\/j.intimp.2024.113709_b0515","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176401","article-title":"The role of the IL-23\/IL-17 pathway in the pathogenesis of spondyloarthritis","volume":"21","author":"Tsukazaki","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b0520","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00296-009-0883-x","article-title":"Expression of IL-23 and IL-17 and effect of IL-23 on IL-17 production in ankylosing spondylitis","volume":"29","author":"Wang","year":"2009","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0525","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nri2225","article-title":"How microorganisms tip the balance between interleukin-12 family members","volume":"8","author":"Goriely","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0530","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b0535","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0540","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.0902796","article-title":"IL-23 receptor regulates unconventional IL-17-producing T cells that control bacterial infections","volume":"184","author":"Riol-Blanco","year":"2010","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0545","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.immuni.2009.08.001","article-title":"Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity","volume":"31","author":"Sutton","year":"2009","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0550","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.immuni.2010.08.013","article-title":"gammadelta T cells enhance autoimmunity by restraining regulatory T cell responses via an interleukin-23-dependent mechanism","volume":"33","author":"Petermann","year":"2010","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0555","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/rheumatology\/keu382","article-title":"IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities","volume":"54","author":"Jansen","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0560","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/s41392-023-01620-3","article-title":"The IL-17 family in diseases: from bench to bedside","volume":"8","author":"Huangfu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b0565","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0570","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2024.113709_b0575","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10928","article-title":"IL-17-producing \u03b3\u03b4 T cells enhance bone regeneration","volume":"7","author":"Ono","year":"2016","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0580","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/BOR.0000000000000069","article-title":"The interleukin-23\/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis","volume":"26","author":"Yeremenko","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b0585","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.4049\/jimmunol.180.8.5167","article-title":"Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion","volume":"180","author":"Rachitskaya","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0590","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/cei.12670","article-title":"The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment","volume":"183","author":"Jethwa","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0595","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis","volume":"30","author":"Mei","year":"2011","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0600","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2567.2009.03240.x","article-title":"Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease","volume":"129","author":"Onishi","year":"2010","journal-title":"Immunology"},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0605","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.immuni.2008.07.018","article-title":"Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction","volume":"29","author":"Ogura","year":"2008","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b0610","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","article-title":"Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis","volume":"14","author":"Gravallese","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113709_b0615","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3389\/fimmu.2014.00425","article-title":"Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells","volume":"5","author":"Osta","year":"2014","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0620","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/art.40468","article-title":"Inflammation intensity-dependent expression of osteoinductive wnt proteins is critical for ectopic new bone formation in ankylosing spondylitis","volume":"70","author":"Li","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0625","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13075-018-1582-3","article-title":"IL-17A induces osteoblast differentiation by activating JAK2\/STAT3 in ankylosing spondylitis","volume":"20","author":"Jo","year":"2018","journal-title":"Arthritis Res. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b0630","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/ar2297","article-title":"IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats","volume":"9","author":"Yago","year":"2007","journal-title":"Arthritis Res. Ther."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b0635","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.4049\/jimmunol.181.8.5720","article-title":"IL-23 inhibits osteoclastogenesis indirectly through lymphocytes and is required for the maintenance of bone mass in mice","volume":"181","author":"Quinn","year":"2008","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0640","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.38291","article-title":"The interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis Th17 and beyond","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0645","doi-asserted-by":"crossref","first-page":"E47","DOI":"10.1016\/S2665-9913(22)00334-4","article-title":"Role of neutrophil interleukin-23 in spondyloarthropathy spectrum disorders","volume":"5","author":"Macleod","year":"2023","journal-title":"Lancet Rheumatol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b0650","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat. Immunol."},{"issue":"7090","key":"10.1016\/j.intimp.2024.113709_b0655","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"issue":"7090","key":"10.1016\/j.intimp.2024.113709_b0660","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature04754","article-title":"Transforming growth factor-beta induces development of the T(H)17 lineage","volume":"441","author":"Mangan","year":"2006","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0665","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3858\/emm.2011.43.1.007","article-title":"Genetic controls of Th17 cell differentiation and plasticity","volume":"43","author":"Dong","year":"2011","journal-title":"Exp. Mol. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0670","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1074\/jbc.M207577200","article-title":"Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17","volume":"278","author":"Aggarwal","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0675","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/art.42476","article-title":"Analysis of single-cell transcriptome and surface protein expression in ankylosing spondylitis identifies OX40-positive and glucocorticoid-induced tumor necrosis factor receptor-positive pathogenic Th17 cells","volume":"75","author":"Yi","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b0680","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1007\/s12325-022-02240-z","article-title":"Levels of peripheral Th17 cells and Th17-related cytokines in patients with ankylosing spondylitis: a meta-analysis","volume":"39","author":"Su","year":"2022","journal-title":"Adv. Ther."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b0685","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/eji.201242569","article-title":"IL-17-producing gammadelta T cells and innate lymphoid cells","volume":"42","author":"Sutton","year":"2012","journal-title":"Eur. J. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b0690","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive gamma\/delta T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b0695","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis gammadeltaT-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0700","doi-asserted-by":"crossref","first-page":"819","DOI":"10.33549\/physiolres.935140","article-title":"Results of flow cytometric detection of gamma-deltaT cells in peripheral blood of patients with ankylosing spondylitis: a pilot study","volume":"72","author":"Man","year":"2023","journal-title":"Physiol. Res."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0705","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/imcb.12011","article-title":"Mucosal-associated invariant T cells in autoimmune and immune-mediated diseases","volume":"96","author":"Rouxel","year":"2018","journal-title":"Immunol. Cell Biol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0710","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","article-title":"IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis","volume":"75","author":"Gracey","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113709_b0715","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3389\/fimmu.2018.01610","article-title":"Increased IL-22- and IL-17A-producing mucosal-associated invariant T cells in the peripheral blood of patients with ankylosing spondylitis","volume":"9","author":"Toussirot","year":"2018","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b0720","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/art.42090","article-title":"Characterization of blood mucosal-associated invariant T cells in patients with axial spondyloarthritis and of resident mucosal-associated invariant T cells from the axial entheses of non-axial spondyloarthritis control patients","volume":"74","author":"Rosine","year":"2022","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2024.113709_b0725","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1128270","article-title":"Mucosal-associated invariant T cells in patients with axial spondyloarthritis","volume":"14","author":"van der Meer","year":"2023","journal-title":"Front Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0730","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nri2800","article-title":"Innate IL-17-producing cells: the sentinels of the immune system","volume":"10","author":"Cua","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0735","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nri3365","article-title":"Innate lymphoid cells\u2013a proposal for uniform nomenclature","volume":"13","author":"Spits","year":"2013","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b0740","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/annrheumdis-2014-206323","article-title":"Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis","volume":"74","author":"Ciccia","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0745","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11926-019-0834-9","article-title":"ILC3 in Axial Spondyloarthritis: the Gut Angle","volume":"21","author":"Mauro","year":"2019","journal-title":"Curr. Rheumatol. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0750","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1136\/ard-2022-223146","article-title":"Card9\/neutrophil signalling axis promotes IL-17A-mediated ankylosing spondylitis","volume":"83","author":"Rosenzweig","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0755","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/ard-2023-224107","article-title":"CD_99 G1 neutrophils modulate osteogenic differentiation of mesenchymal stem cells in the pathological process of ankylosing spondylitis","volume":"83","author":"Feng","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0760","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.369","article-title":"Single-cell analysis reveals innate immunity dynamics in ankylosing spondylitis","volume":"11","author":"Liu","year":"2021","journal-title":"Clin. Transl. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0765","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10067-017-3887-z","article-title":"Changes and clinical significance of CD8+CD122+T cells in the peripheral blood of patients with ankylosing spondylitis","volume":"37","author":"Han","year":"2018","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0770","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41419-019-1448-x","article-title":"Abnormal inhibition of osteoclastogenesis by mesenchymal stem cells through the miR-4284\/CXCL5 axis in ankylosing spondylitis","volume":"10","author":"Liu","year":"2019","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b0775","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/s41419-019-1586-1","article-title":"Enhanced osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis: a study based on a three-dimensional biomimetic environment","volume":"10","author":"Zheng","year":"2019","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0780","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar3257","article-title":"Reduced immunomodulation potential of bone marrow-derived mesenchymal stem cells induced CCR4+CCR6+ Th\/Treg cell subset imbalance in ankylosing spondylitis","volume":"13","author":"Wu","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0785","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/BOR.0000000000000945","article-title":"Evidence in support of the bone marrow as the primary lesion in axial spondyloarthritis","volume":"35","author":"Maksymowych","year":"2023","journal-title":"Curr. Opin. Rheumatol."},{"issue":"14","key":"10.1016\/j.intimp.2024.113709_b0790","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abl8054","article-title":"CXCL12\/CXCR4-Rac1-mediated migration of osteogenic precursor cells contributes to pathological new bone formation in ankylosing spondylitis","volume":"8","author":"Cui","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0795","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25710-4","article-title":"TNF-\u03b1-mediated m A modification of ELMO1 triggers directional migration of mesenchymal stem cell in ankylosing spondylitis","volume":"12","author":"Xie","year":"2021","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0800","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012109","article-title":"Aberrant upregulation of CaSR promotes pathological new bone formation in ankylosing spondylitis","volume":"12","author":"Li","year":"2020","journal-title":"Embo Mol. Med."},{"key":"10.1016\/j.intimp.2024.113709_b0805","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2121-9-52","article-title":"Prolonged exposure to bacterial toxins downregulated expression of toll-like receptors in mesenchymal stromal cell-derived osteoprogenitors","volume":"9","author":"Mo","year":"2008","journal-title":"BMC Cell Biol."},{"issue":"20","key":"10.1016\/j.intimp.2024.113709_b0810","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1089\/scd.2019.0039","article-title":"A study of the immunoregulatory function of TLR3 and TLR4 on mesenchymal stem cells in ankylosing spondylitis","volume":"28","author":"Li","year":"2019","journal-title":"Stem Cells Dev."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0815","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26750-6","article-title":"Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis","volume":"12","author":"Shao","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0820","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/ard-2022-223428","article-title":"Piezo1-mediated mechanotransduction promotes entheseal pathological new bone formation in ankylosing spondylitis","volume":"82","author":"Chen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0825","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/annrheumdis-2021-220002","article-title":"Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis","volume":"80","author":"Li","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b0830","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/art.41180","article-title":"Negative regulation of osteoclast commitment by intracellular protein phosphatase magnesium-dependent 1A","volume":"72","author":"Kwon","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0835","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/art.38404","article-title":"Histomorphologic and histomorphometric characteristics of zygapophyseal joint remodeling in ankylosing spondylitis","volume":"66","author":"Bleil","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2024.113709_b0840","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.2147\/JIR.S439604","article-title":"Fibroblast insights into the pathogenesis of ankylosing spondylitis","volume":"16","author":"Liu","year":"2023","journal-title":"J. Inflamm. Res."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b0845","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/art.39715","article-title":"Granulation tissue eroding the subchondral bone also promotes new bone formation in ankylosing spondylitis","volume":"68","author":"Bleil","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0850","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-021-00140-6","article-title":"Chondrogenesis mediates progression of ankylosing spondylitis through heterotopic ossification","volume":"9","author":"Yu","year":"2021","journal-title":"Bone Res."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0855","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10067-014-2663-6","article-title":"Wnt signaling in ankylosing spondylitis","volume":"33","author":"Corr","year":"2014","journal-title":"Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0860","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1073\/pnas.96.7.3546","article-title":"Biochemical characterization of Wnt-frizzled interactions using a soluble, biologically active vertebrate Wnt protein","volume":"96","author":"Hsieh","year":"1999","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b0865","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nrrheum.2013.25","article-title":"To Wnt or not to Wnt: the bone and joint health dilemma","volume":"9","author":"Lories","year":"2013","journal-title":"Nat. Rev. Rheumatol."},{"issue":"22","key":"10.1016\/j.intimp.2024.113709_b0870","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1101\/gad.1957710","article-title":"Canonical and noncanonical Wnts use a common mechanism to activate completely unrelated coreceptors","volume":"24","author":"Grumolato","year":"2010","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0875","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.abb.2011.12.019","article-title":"The many roles of PTK7: a versatile regulator of cell-cell communication","volume":"524","author":"Peradziryi","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0880","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41392-023-01330-w","article-title":"Osteoarthritis: pathogenic signaling pathways and therapeutic targets","volume":"8","author":"Yao","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5573","key":"10.1016\/j.intimp.2024.113709_b0885","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1126\/science.1071549","article-title":"The promise and perils of Wnt signaling through beta-catenin","volume":"296","author":"Moon","year":"2002","journal-title":"Science"},{"issue":"5831","key":"10.1016\/j.intimp.2024.113709_b0890","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1126\/science.1137065","article-title":"Wnt induces LRP6 signalosomes and promotes dishevelled-dependent LRP6 phosphorylation","volume":"316","author":"Bilic","year":"2007","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0895","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41413-024-00342-8","article-title":"Wnt\/beta-catenin signaling components and mechanisms in bone formation, homeostasis, and disease","volume":"12","author":"Hu","year":"2024","journal-title":"Bone Res."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b0900","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140119","article-title":"Updating the Wnt pathways","volume":"34","author":"Yu","year":"2014","journal-title":"Biosci. Rep."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b0905","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1161\/ATVBAHA.119.312612","article-title":"Dkk (Dickkopf) proteins","volume":"39","author":"Baetta","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0910","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/nyas.12968","article-title":"Wnt\/beta-catenin signaling plays a key role in the development of spondyloarthritis","volume":"1364","author":"Xie","year":"2016","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b0915","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/ard.2008.102046","article-title":"Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints","volume":"69","author":"Uderhardt","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113709_b0920","doi-asserted-by":"crossref","first-page":"1193357","DOI":"10.3389\/fimmu.2023.1193357","article-title":"Serum DKK-1 level in ankylosing spondylitis: insights from meta-analysis and Mendelian randomization","volume":"14","author":"Fang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.113709_b0925","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cca.2018.03.010","article-title":"Dickkopf-1 in ankylosing spondylitis: review and meta-analysis","volume":"481","author":"Wu","year":"2018","journal-title":"Clin. Chim. Acta"},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0930","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23126660","article-title":"DKK-1 is underexpressed in mesenchymal stem cells from patients with ankylosing spondylitis and further downregulated by IL-17","volume":"23","author":"Daoussis","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0935","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/art.40770","article-title":"Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis","volume":"71","author":"van Tok","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0940","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8515-6","article-title":"Bone as a target organ in rheumatic disease: impact on osteoclasts and osteoblasts","volume":"51","author":"Baum","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0945","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cytogfr.2012.06.003","article-title":"The \u201cbone morphogenic proteins\u201d pathways in bone and joint diseases: translational perspectives from physiopathology to therapeutic targets","volume":"24","author":"Biver","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"issue":"Pt 9","key":"10.1016\/j.intimp.2024.113709_b0950","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1242\/jcs.01036","article-title":"Smad7 is required for TGF-beta-induced activation of the small GTPase Cdc42","volume":"117","author":"Edlund","year":"2004","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.intimp.2024.113709_b0955","doi-asserted-by":"crossref","first-page":"16009","DOI":"10.1038\/boneres.2016.9","article-title":"TGF-beta and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease","volume":"4","author":"Wu","year":"2016","journal-title":"Bone Res."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0960","doi-asserted-by":"crossref","first-page":"272","DOI":"10.7150\/ijbs.2929","article-title":"TGF-beta and BMP signaling in osteoblast differentiation and bone formation","volume":"8","author":"Chen","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b0965","first-page":"2731","article-title":"Mechanism of triptolide in treating ankylosing spondylitis through the anti\u2011ossification effect of the BMP\/Smad signaling pathway","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0970","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41413-021-00140-6","article-title":"Chondrogenesis mediates progression of ankylosing spondylitis through heterotopic ossification","volume":"9","author":"Yu","year":"2021","journal-title":"Bone Res."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b0975","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1038\/s41467-021-26750-6","article-title":"Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis","volume":"12","author":"Shao","year":"2021","journal-title":"Nat. Commun."},{"issue":"16","key":"10.1016\/j.intimp.2024.113709_b0980","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20163981","article-title":"Regulation of hedgehog signaling offers a novel perspective for bone homeostasis disorder treatment","volume":"20","author":"Lv","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2024.113709_b0985","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.940455","article-title":"Role of the hedgehog signaling pathway in rheumatic diseases: an overview","volume":"13","author":"Su","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b0990","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.berh.2010.03.001","article-title":"Pharmacotherapy: concepts of pathogenesis and emerging treatments. Novel targets in bone and cartilage","volume":"24","author":"Beyer","year":"2010","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b0995","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.23985","article-title":"Regulation of articular chondrocyte proliferation and differentiation by indian hedgehog and parathyroid hormone-related protein in mice","volume":"58","author":"Chen","year":"2008","journal-title":"Arthritis Rheum."},{"issue":"20","key":"10.1016\/j.intimp.2024.113709_b1000","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1002\/anie.200906967","article-title":"Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives","volume":"49","author":"Heretsch","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b1005","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/nm.2055","article-title":"Modulating hedgehog signaling can attenuate the severity of osteoarthritis","volume":"15","author":"Lin","year":"2009","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b1010","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/art.38325","article-title":"Inactivation of patched1 in murine chondrocytes causes spinal fusion without inflammation","volume":"66","author":"Dittmann","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b1015","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.semarthrit.2015.01.004","article-title":"Anti-TNFalpha treatment decreases the previously increased serum Indian Hedgehog levels in patients with ankylosing spondylitis and affects the expression of functional Hedgehog pathway target genes","volume":"44","author":"Daoussis","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2024.113709_b1020","first-page":"68","article-title":"Update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"2016","author":"van der Heijde","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b1025","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41584-023-01034-z","article-title":"Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis","volume":"19","author":"Bautista-Molano","year":"2023","journal-title":"Nat. Rev. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1030","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ard-2022-223297","article-title":"Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Ortolan","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113709_b1035","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/bjsports-2018-099943","article-title":"High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients","volume":"54(5)","author":"Sveaas","year":"2020","journal-title":"Brit J Sport Med."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b1040","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00296-016-3441-3","article-title":"Effectiveness of ultrasound treatment applied with exercise therapy on patients with ankylosing spondylitis: a double-blind, randomized, placebo-controlled trial","volume":"36","author":"Karamanlioglu","year":"2016","journal-title":"Rheumatol. Int."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b1045","first-page":"30","article-title":"Randomized, controlled trial: efficacy of ultrasound and exercise in patients with ankylosing spondylitis","volume":"24","author":"Sun","year":"2018","journal-title":"Altern. Ther. Health M."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b1050","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1097\/BRS.0000000000003800","article-title":"When can one-level pedicle subtraction osteotomy obtain satisfied outcomes for severe thoracolumbar kyphosis with global kyphosis \u226580\u00b0 in ankylosing spondylitis a comparison with two-level pedicle subtraction osteotomy","volume":"46","author":"Huang","year":"2021","journal-title":"Spine"},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b1055","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.arth.2020.06.048","article-title":"Do all rigid and unbalanced spines present the same risk of dislocation after total hip arthroplasty? A comparison study between patients with ankylosing spondylitis and history of spinal fusion","volume":"35","author":"Katakam","year":"2020","journal-title":"J. Arthroplast."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1060","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3171\/2018.12.SPINE18752","article-title":"Does relocation of the apex after osteotomy affect surgical and clinical outcomes in patients with ankylosing spondylitis and thoracolumbar kyphosis?","volume":"31","author":"Liu","year":"2019","journal-title":"J. Neurosurg.-Spine."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b1065","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1177\/2192568220980716","article-title":"Does the level of pedicle subtraction osteotomy affect the surgical outcomes in ankylosing spondylitis-related thoracolumbar kyphosis with the same curve pattern?","volume":"12","author":"Tang","year":"2022","journal-title":"Glob. Spine J."},{"issue":"23","key":"10.1016\/j.intimp.2024.113709_b1070","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/BRS.0000000000003095","article-title":"Two-level osteotomy for the corrective surgery of severe kyphosis from ankylosing spondylitis","volume":"44","author":"Zhong","year":"2019","journal-title":"Spine"},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b1075","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/art.41042","article-title":"2019 Update of the American College of Rheumatology\/spondylitis association of america\/spondyloarthritis research and treatment network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b1080","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2015-207677","article-title":"Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials","volume":"75","author":"Wang","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b1085","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/art.39474","article-title":"Six-week treatment of axial spondyloarthritis patients with an optimal dose of nonsteroidal antiinflammatory drugs: early response to treatment in signal intensity on magnetic resonance imaging of the sacroiliac joints","volume":"68","author":"Varkas","year":"2016","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b1090","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","article-title":"Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)","volume":"75","author":"Sieper","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b1095","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/art.41206","article-title":"Effect of therapy on radiographic progression in axial spondyloarthritis: a systematic review and meta-analysis","volume":"72","author":"Karmacharya","year":"2020","journal-title":"Arthritis Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b1100","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1136\/ard-2023-225406","article-title":"Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis","volume":"83","author":"Kim","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113709_b1105","article-title":"Sulfasalazine for ankylosing spondylitis","volume":"11","author":"Chen","year":"2014","journal-title":"Cochrane Db. Syst. Rev."},{"key":"10.1016\/j.intimp.2024.113709_b1110","doi-asserted-by":"crossref","unstructured":"J.M. Chen M.M.S. Veras C. Liu J.F. Lin, Methotrexate for ankylosing spondylitis, Cochrane Db. Syst. Rev. (2) (2013). doi.org\/ARTN CD004524 10.1002\/14651858.CD004524.pub4.","DOI":"10.1002\/14651858.CD004524.pub4"},{"key":"10.1016\/j.intimp.2024.113709_b1115","doi-asserted-by":"crossref","DOI":"10.1080\/03009742.2024.2346411","article-title":"Efficacy and safety of iguratimod combined with celecoxib in active axial spondyloarthritis: a randomized, double-blind, placebo-controlled study","author":"Chen","year":"2024","journal-title":"Scand. J. Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b1120","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2019-216741","article-title":"Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence","volume":"79","author":"Koo","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.40661","article-title":"Impact of tumor necrosis factor inhibitor versus nonsteroidal antiinflammatory drug treatment on radiographic progression in early ankylosing spondylitis: its relationship to inflammation control during treatment","volume":"71","author":"Park","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","article-title":"TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort","volume":"77","author":"Molnar","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b1135","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1002\/art.42144","article-title":"Treatment with tumor necrosis factor inhibitors is associated with a time-shifted retardation of radiographic sacroiliitis progression in patients with axial spondyloarthritis: 10-year results from the German spondyloarthritis inception cohort","volume":"74","author":"Torgutalp","year":"2022","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b1140","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/annrheumdis-2022-222324","article-title":"Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis","volume":"81","author":"Torgutalp","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b1145","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/annrheumdis-2020-218304","article-title":"Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo","volume":"80","author":"Menegatti","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b1150","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/annrheumdis-2012-202533","article-title":"Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial","volume":"73","author":"Huang","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b1155","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2013-204185","article-title":"Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up","volume":"74","author":"Kneepkens","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1160","doi-asserted-by":"crossref","first-page":"E35","DOI":"10.1016\/S2665-9913(19)30013-X","article-title":"IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial","volume":"1","author":"Xu","year":"2019","journal-title":"Lancet Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b1165","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1136\/annrheumdis-2014-205213","article-title":"Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up","volume":"74","author":"Kneepkens","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b1170","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/art.40786","article-title":"Progression of structural damage in the sacroiliac joints in patients with early axial spondyloarthritis during long-term anti-tumor necrosis factor treatment: six-year results of continuous treatment with etanercept","volume":"71","author":"Rodriguez","year":"2019","journal-title":"Arthrit. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b1175","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","article-title":"Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register","volume":"76","author":"Lie","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b1180","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","article-title":"The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial","volume":"73","author":"Braun","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b1185","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/annrheumdis-2014-205862","article-title":"Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study","volume":"74","author":"Deodhar","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113709_b1190","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/annrheumdis-2012-eular.3080","article-title":"Golimumab 3-year safety update: an analysis of pooled data from the long term extensions of randomized, double-blind, placebo-controlled studies in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"71","author":"Kay","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b1195","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"Denmark ADr, A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1200","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/art.40324","article-title":"Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab","volume":"70","author":"Tweehuysen","year":"2018","journal-title":"Arthrit. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b1205","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jaci.2018.05.015","article-title":"Paradoxical psoriasis following anti-TNF therapy in ankylosing spondylitis: a population-based cohort study","volume":"142","author":"Bae","year":"2018","journal-title":"J. Allerg. Clin. Immun."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b1210","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2019-216693","article-title":"Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden","volume":"79","author":"Kopp","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b1215","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/ard-2022-222641","article-title":"Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data analysis from the European Network of Pregnancy Registries in Rheumatology (EuNeP)","volume":"81","author":"Meissner","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b1220","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40265-016-0598-8","article-title":"Secukinumab: a review in ankylosing spondylitis","volume":"76","author":"Blair","year":"2016","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b1225","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis a phase III randomized trial (MEASURE 1)","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthrit. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b1230","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","article-title":"Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study","volume":"76","author":"Braun","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b1235","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/annrheumdis-2021-220420","article-title":"Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?","volume":"80","author":"Lindstr\u00f6m","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"10163","key":"10.1016\/j.intimp.2024.113709_b1240","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b1245","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b1250","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/ard-2022-222731","article-title":"Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study","volume":"82","author":"Landew\u00e9","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113709_b1255","doi-asserted-by":"crossref","unstructured":"M. Dougados J.C.C. Wei R. Landew\u00e9 Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W), Ann. Rheum. Dis. 79(6) (2020) 176. doi.org\/ARTN e75 10.1136\/annrheumdis-2019-216118corr1.","DOI":"10.1136\/annrheumdis-2019-216118corr1"},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b1260","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b1265","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1002\/art.42282","article-title":"Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: three-year results from a phase iib randomized controlled trial and its open-label extension study","volume":"74","author":"Baraliakos","year":"2022","journal-title":"Arthrit. Rheumatol."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1270","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2013-204231","article-title":"Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study","volume":"73","author":"Landew\u00e9","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b1275","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","article-title":"Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial","volume":"77","author":"van der Heijde","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.113709_b1280","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/art.38973","article-title":"Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis","volume":"67","author":"Sieper","year":"2015","journal-title":"Arthrit. Rheumatol."},{"key":"10.1016\/j.intimp.2024.113709_b1285","doi-asserted-by":"crossref","unstructured":"Landew\u00e9 RB, van der Heijde D, Dougados M, Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction, Ann. Rheum. Dis. 79(9) (2020) 920. doi.org\/ARTN e120 10.1136\/annrheumdis-2019-216839corr1.","DOI":"10.1136\/annrheumdis-2019-216839corr1"},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b1290","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1136\/annrheumdis-2020-219406","article-title":"Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial","volume":"80","author":"Wei","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b1295","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.1136\/annrheumdis-2020-218719","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"82","author":"Mehta","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b1300","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41584-023-01072-7","article-title":"Exploring the latest advances in axial spondyloarthritis management","volume":"20","author":"Benavent","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b1305","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b1310","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b1315","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/ard-2022-222608","article-title":"Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial","volume":"81","author":"van der Heijde","year":"2022","journal-title":"Ann. Rheum. Dis."},{"issue":"10214","key":"10.1016\/j.intimp.2024.113709_b1320","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1325","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/art.41911","article-title":"Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension","volume":"74","author":"Deodhar","year":"2022","journal-title":"Arthrit. Rheumatol."},{"issue":"10162","key":"10.1016\/j.intimp.2024.113709_b1330","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b1335","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b1340","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1093\/rheumatology\/keab275","article-title":"Glucocorticoids in spondyloarthritis-systematic review and real-world analysis","volume":"60","author":"Dhir","year":"2021","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b1345","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006957","article-title":"A long-term, observational cohort study on the safety of low-dose glucocorticoids in ankylosing spondylitis: adverse events and effects on bone mineral density, blood lipid and glucose levels and body mass index","volume":"5","author":"Zhang","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1350","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/annrheumdis-2012-203055","article-title":"Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial","volume":"73","author":"Haibel","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b1355","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1136\/ard.2009.126706","article-title":"Mixed response to tocilizumab for ankylosing spondylitis","volume":"69","author":"Henes","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"7","key":"10.1016\/j.intimp.2024.113709_b1360","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3899\/jrheum.110265","article-title":"Ankylosing spondylitis refractory to tumor necrosis factor blockade responds to tocilizumab","volume":"38","author":"Cohen","year":"2011","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b1365","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3109\/s10165-011-0416-9","article-title":"Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis","volume":"21","author":"Shima","year":"2011","journal-title":"Mod. Rheumatol."},{"issue":"6","key":"10.1016\/j.intimp.2024.113709_b1370","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","article-title":"Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)","volume":"74","author":"Sieper","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b1375","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2665-9913(24)00099-7","article-title":"Granulocyte-macrophage colony-stimulating factor neutralisation in patients with axial spondyloarthritis in the UK (NAMASTE): a randomised, double-blind, placebo-controlled, phase 2 trial (vol 6, pg e537, 2024)","volume":"6","author":"Worth","year":"2024","journal-title":"Lancet Rheumatol."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b1380","first-page":"58","article-title":"Targeting PI3K\/mTOR signaling with potent, selective and orally-available small-molecule inhibitors of eIF4E","volume":"18","author":"Parker","year":"2020","journal-title":"Mol. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b1385","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1172\/JCI126567","article-title":"TYK2 inhibition reduces type 3 immunity and modifies disease progression in murine spondyloarthritis","volume":"130","author":"Gracey","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2024.113709_b1390","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-023-02613-z","article-title":"Targeted depletion of TRBV9 T cells as immunotherapy in a patient with ankylosing spondylitis","author":"Britanova","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2024.113709_b1395","doi-asserted-by":"crossref","unstructured":"Zheng G, Peng XS, Zhang YH, Wang P, Xie ZY, Li JT, Liu WJ, Ye GW, Lin YC, Li GJ, Liu HT, Zeng CY, Li LH, Wu YF, Shen HY, A novel Anti-ROS osteoblast-specific delivery system for ankylosing spondylitis treatment via suppression of both inflammation and pathological new bone formation, J Nanobiotechnol. 2023;21(1). doi.org\/ARTN 168 10.1186\/s12951-023-01906-2.","DOI":"10.1186\/s12951-023-01906-2"},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b1400","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/1756-185X.14484","article-title":"Ankylosing spondylitis occurring in a patient with Behcet disease after chronic brucellosis infection: a case report and review of the literature","volume":"26","author":"Yilmaz","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b1405","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.berh.2014.10.009","article-title":"The role of mechanical stress in the pathogenesis of spondyloarthritis and how to combat it","volume":"28","author":"Jacques","year":"2014","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.intimp.2024.113709_b1410","first-page":"3493","article-title":"New insights into IL-17\/IL-23 signaling in ankylosing spondylitis (Review)","volume":"20","author":"Chisalau","year":"2020","journal-title":"Exp. Ther. Med."},{"issue":"8","key":"10.1016\/j.intimp.2024.113709_b1415","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1136\/annrheumdis-2015-208194","article-title":"NSAIDs in axial spondyloarthritis: to be continued","volume":"75","author":"Varkas","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2024.113709_b1420","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1136\/ard-2023-224699","volume":"83","author":"Proft","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2024.113709_b1425","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1136\/annrheumdis-2014-eular.3351","article-title":"A tailored approach to reduce dose of anti-tnf drugs is equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over one year: a matched observational study","volume":"73","author":"Zavada","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1430","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/annrheumdis-2013-203934","article-title":"Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis","volume":"74","author":"van Sijl","year":"2015","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2024.113709_b1435","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/art.39416","article-title":"Risk of subsequent infection among patients receiving tumor necrosis factor inhibitors and other disease-modifying antirheumatic drugs","volume":"68","author":"Accortt","year":"2016","journal-title":"Arthrit. Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b1440","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/annrheumdis-2020-217927","article-title":"Paradoxical gastrointestinal effects of interleukin-17 blockers","volume":"79","author":"Fauny","year":"2020","journal-title":"Ann. Rheum. Dis."},{"issue":"26","key":"10.1016\/j.intimp.2024.113709_b1445","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A Inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"New Engl J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.113709_b1450","first-page":"258","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis, arthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2024.113709_b1455","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.intimp.2024.113709_b1460","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/s41584-019-0294-7","article-title":"The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis","volume":"15","author":"Sieper","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"issue":"11","key":"10.1016\/j.intimp.2024.113709_b1465","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","article-title":"Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression","volume":"78","author":"Cuthbert","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.intimp.2024.113709_b1470","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/annrheumdis-2013-203425","article-title":"Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann. Rheum. Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924022318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924022318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:41:50Z","timestamp":1734655310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924022318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":294,"alternative-id":["S1567576924022318"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113709","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ankylosing spondylitis: From pathogenesis to therapy","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"113709"}}